In a separate univariable model using molecular subtype (reference category: triple-negative), both luminal A and luminal B/HER2− tumours were associated with significantly higher odds of SLNB positivity (OR 6.59, 95% CI 1.64–26.43; p = 0.008 and OR 5.33, 95% CI 1.18–24.21; p = 0.030, respectively), whereas luminal B/HER2+ and HER2-enriched subtypes did not differ significantly from triple-negative disease (both p > 0.60). Here, ERBB2 is linked to neoplasm.